Novo Nordisk | NVO - Debt


Novo Nordisk reported DKK118.72B in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
ANI Pharmaceuticals USD 617.04M 3.28M Dec/2025
Aurora Cannabis CAD 23.86M 76.48M Mar/2026
Bausch Health Companies USD 20.85B 191M Dec/2025
Bristol-Myers Squibb USD 47.14B 3.9B Dec/2025
Canopy Growth CAD 278.71M 19.38M Mar/2026
Corcept Therapeutics USD 6.11M 251K Dec/2025
Drreddys Laboratories INR 77.34B 9.61B Mar/2026
Eli Lilly USD 42.5B 3.6M Dec/2025
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Merck USD 49.34B 7.97B Dec/2025
Nektar Therapeutics USD 0 0 Jun/2022
Novartis USD 47B 11.62B Mar/2026
Novo Nordisk DKK 118.72B 61.75B Mar/2025
Novo Nordisk DKK 118.72B 15.94B Mar/2025
Pacira USD 367.66M 4.53M Mar/2026
Perrigo USD 3.64B 4.5M Dec/2025
Phibro Animal Health USD 474.17M 730K Sep/2024
Prestige Brands USD 1.08B 38.27M Dec/2025
Sanofi EUR 20.33B 1.43B Dec/2025
Supernus Pharmaceuticals USD 40.98M 1.23M Dec/2025
Zoetis USD 9.24B 1.96B Dec/2025